Skip to Main Content

Paper Details

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Cancer Cell
127
2021
DOP, Durvalumab, Gene expression, HER2, HER2-negative, HER2-negative breast cancer, HER2-negative stage II/III breast cancer, HR, HR-positive/, HR-positive/HER2-negative cancers, MP1, MP1 cancers, PARP, PD-L1, TNBC, breast cancer, durvalumab, hormone receptor, mast cell, olaparib, paclitaxel, participants, patients, stage II/III, triple-negative breast cancer
Author NameAffiliation
Lajos PusztaiYale Cancer Center, Yale School of Medicine
Christina YauHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Christina YauHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Denise M WolfUniversity of California san francisco
Judy C BougheyMayo Clinic
Rita NandaUniversity of Chicago
Claudine IsaacsGeorgetown University
Teresa HelstenMoores Cancer Center, University of California San Diego
Minetta C LiuMayo Clinic
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University
Scott M Berry
Richard B SchwabMoores Cancer Center, University of California San Diego
William F SymmansUniversity of Texas MD Anderson Cancer Center
Laura J Van't VeerHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Donald A Berry
  • 1 - 16

Datasets

Release 1.2